SAN DIEGO--(BUSINESS WIRE)--Feb. 14, 2006--Ambit Biosciences today announced that it has expanded the panel of kinases available through its KinomeScan kinase profiling technology to 234 kinases, including many clinically-relevant kinases and several drug-resistant or disease-causing mutant kinases. Additionally, the company announced that it generated approximately 300,000 data points, defined as one small molecule screened against one kinase, during the past year by screening both its own and its partners' libraries of compounds against the robust KinomeScan panel.
